The pandemic proved drug development can move faster. Now 82% of FDA submissions include RWE, but data harmonization and traceability remain key hurdles. Pharma can overcome this by "starting with the end in mind." Read how in @MedCityNews
:
FDA RWE Submissions Accelerate Pharma Drug Development Process
By
–